Search

Corvus Pharmaceuticals Inc

Geschlossen

10.01 -2.25

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.76

Max

10.05

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+186.64% upside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-245M

879M

Vorheriger Eröffnungskurs

12.26

Vorheriger Schlusskurs

10.01

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Okt. 2026, 23:56 UTC

Scholar Rock Holding Corporation's shares are trading modestly lower in after-market hours, retracing from an early peak following a brief uptick after Friday's close.

30. Okt. 2026, 23:56 UTC

Surgery Partners, Inc. is trading modestly lower in after-market hours, settling at its lowest point despite a brief recovery earlier in the session.

30. Okt. 2026, 23:56 UTC

Aquestive Therapeutics, Inc. is trading modestly higher in after-market hours following a notable increase after an initial dip earlier in the session.

30. Okt. 2026, 23:56 UTC

Patterson-UTI Energy Inc shares traded modestly lower in after-market hours, retracing some gains after a brief improvement following Friday's close.

30. Okt. 2026, 23:56 UTC

Avantor, Inc. shares are declining in after-market trading, continuing a downward trend since Friday's close and reaching their lowest point late in the session.

30. Okt. 2026, 23:56 UTC

Xometry, Inc. is trading modestly higher in after-market hours, reaching a peak since Friday's close despite an initial dip.

30. Okt. 2026, 23:56 UTC

Social Media

Take-Two Interactive Software, Inc. shares are trading modestly higher in after-market hours.

30. Okt. 2026, 23:56 UTC

Krispy Kreme, Inc. shares are trading modestly lower in after-market hours, following a recent decline.

30. Okt. 2026, 23:56 UTC

LyondellBasell Industries N.V. is trading lower in after-market hours, with a cumulative return decrease from a low of -1.30% to -0.58% since Friday's close.

30. Okt. 2026, 23:56 UTC

Canadian Solar Inc. is trading modestly lower in after-market hours, following a slight recovery from an earlier decline at the market close.

30. Okt. 2026, 23:56 UTC

The Nikkei 225 Index declined during after-market hours, continuing a downward trend amid broader market weakness and slowing business activity indicated by Chicago PMI data.

30. Okt. 2026, 23:56 UTC

ConocoPhillips shares are trading lower in after-market hours, having retraced from an earlier peak and remaining down since Friday's close.

30. Okt. 2026, 23:56 UTC

Pool Corporation shares traded modestly lower in after-market hours, continuing a decline that began after Friday's close.

30. Okt. 2026, 23:56 UTC

Wingstop Inc. is trading lower in after-market hours, having earlier dipped as much as 1.51% from Friday's close.

30. Okt. 2026, 23:56 UTC

Fastenal Company shares are trading modestly higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

30. Okt. 2026, 23:56 UTC

AAON, Inc. shares are modestly higher in after-market trading, recovering from recent weakness.

30. Okt. 2026, 23:52 UTC

Australia's Balance of Trade report on November 5 expected to show AUD 1 billion surplus, reflecting strong resource exports and positive market sentiment.

30. Okt. 2026, 23:52 UTC

Brazil's Industrial Production MoM data release on November 5, 2026, raises cautious market expectations amid ongoing declines and economic challenges.

30. Okt. 2026, 23:51 UTC

Champion Homes Inc. is trading modestly lower in after-market hours, having retraced from a brief peak earlier in the session.

30. Okt. 2026, 23:51 UTC

Sarepta Therapeutics, Inc. is trading modestly higher in after-market hours after a strong upward movement from a low point shortly after the market closed.

30. Okt. 2026, 23:51 UTC

Social Media

In after-market hours, Lowe's shares traded lower, retracing from earlier gains to below Friday's close, despite discussions on its dividend performance.

30. Okt. 2026, 23:51 UTC

Herc Holdings Inc. is trading lower in after-market hours, reversing an earlier uptick and declining since Friday's close.

30. Okt. 2026, 23:51 UTC

Cabaletta Bio, Inc. shares declined in after-market trading after a volatile session, currently positioned below its 20-day moving average and near the month's lower range.

30. Okt. 2026, 23:51 UTC

The New York Times Company is trading higher in after-market hours, reaching a high above its 20-day moving average and near the upper end of its one-month range.

30. Okt. 2026, 23:51 UTC

W. P. Carey Inc. has advanced modestly in after-market trading, reaching a high point near the upper end of its one-month trading range.

30. Okt. 2026, 23:51 UTC

Axsome Therapeutics, Inc. is advancing in after-market trading.

30. Okt. 2026, 23:51 UTC

News

FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.

30. Okt. 2026, 23:51 UTC

News

BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.

30. Okt. 2026, 23:51 UTC

Goodyear Tire & Rubber Co is trading modestly higher in after-market hours, recovering from earlier fluctuations during the session.

30. Okt. 2026, 23:51 UTC

News

Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

186.64% Vorteil

12-Monats-Prognose

Durchschnitt 28.75 USD  186.64%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat